



Mechanisms of Cancer Cells Escape from Immune Surveillance: The Focus on Epigenetic and Pro-inflammatory Adaptations

Guest Editors:

Dr. Olga Sukocheva

College of Nursing and Health Sciences, Flinders Medical Centre, Flinders University, Adelaide 5001, Australia

Dr. Margarita Neganova

Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Severnii pr-d 1, Chernogolovka 142432, Russia

Deadline for manuscript submissions:

30 September 2024

Message from the Guest Editors

Dear Colleagues,

Anti-cancer surveillance is one of the most important functions of the immune system as it helps to eliminate transformed and malfunctioning cells. However, many cancer cells manage to hide from the screening for elimination and/or survive the immune defense mechanisms. Cancer cell survival results in the development of resistance, metastasis, and cancer recurrence. This Special Issue of *Cancers* presents current advances in the understanding of molecular mechanisms of cancer cell escape from immune surveillance and development of cancer chemo- and radio-resistance. Also focuses on the description of novel anticancer methodologies that target epigenetic gene regulation and the pro-inflammatory tumor microenvironment. Original research manuscripts, insightful reviews, and idea-provoking letters that discuss novel mechanisms of cancer cells' adaptations to immune surveillance, survival, and resistance are invited.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)